Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
363people in the A 52-week, Multi-centre, Open-labelled, Randomised trial, from 2012
360of them with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
pretrial OAD in combination with liraglutide 0.9 mg/day
pretrial OAD in combination with an additional OAD
Probably lowered long-term blood sugar−0.27
Probably lowered fasting blood sugar−5.47
randomisedthe abstract, start to end
… [estimated mean treatment difference -0.27% (95% confidence interval (CI) -0.44, -0.09; P = 0.0026)]; reductions in mean fasting plasma glucose levels were also greater with liraglutide [estimated mean difference -5.47 mg/dL (-0.30 mmol/L; 95% CI: …
← favours treatmentfavours comparator →
could be chanceGlycosylated hemoglobinpretrial OAD in combination with liraglutide 0.9 mg/day vs pretrial OAD in combination with an additional OAD
−0.27−0.44 to −0.09
Fasting plasma glucose levelspretrial OAD in combination with liraglutide 0.9 mg/day vs pretrial OAD in combination with an additional OAD
−5.47−10.8 to −0.10
GLP-1 receptor agonistsGlycemic control
1 / 4